Deep Track Capital, LP: AXSOME THERAPEUTICS (AXSM): Quarterly 13F Position History
As of Q1 2026, Deep Track Capital, LP reported 1,100,000 shares of AXSOME THERAPEUTICS (AXSM), worth $185.9M and representing 3.8% of its 13F equity book. Quarter-over-quarter share count change: 50,000 (-4.3%) . The position first appeared in Q2 2023 and has been disclosed across 12 13F-HR filings in Pactolio's tracked window.
- 1,100,000Shares Held (Latest Filing)
- $185.9MReported Market Value (Latest Filing)
- 3.8%Portfolio Weight (% of 13F Equity Book)
- 50,000Quarter-over-Quarter Share Change
- -$24.1MQuarter-over-Quarter Value Change
- 1,852,784Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 12 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,100,000 | 50,000 | -4.3% | $185.9M | 3.8% | $169.0 |
| Q4 2025 | 1,150,000 | +250,000 | +27.8% | $210.0M | 4.8% | $182.6 |
| Q3 2025 | 900,000 | +98,629 | +12.3% | $109.3M | 3.1% | $121.5 |
| Q2 2025 | 801,371 | +801,371 | — | $83.7M | 2.7% | $104.4 |
| Q1 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2024 | 0 | 857,219 | -100.0% | $0 | 0.0% | — |
| Q3 2024 | 857,219 | 995,565 | -53.7% | $77.0M | 2.5% | $89.9 |
| Q2 2024 | 1,852,784 | +548,063 | +42.0% | $149.1M | 4.5% | $80.5 |
| Q1 2024 | 1,304,721 | +304,721 | +30.5% | $104.1M | 3.0% | $79.8 |
| Q4 2023 | 1,000,000 | 140,745 | -12.3% | $79.6M | 2.8% | $79.6 |
| Q3 2023 | 1,140,745 | +756,545 | +196.9% | $79.7M | 3.1% | $69.9 |
| Q2 2023 | 384,200 | — | — | $27.6M | 1.3% | $71.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Deep Track Capital, LP first disclose a AXSM position in 13F-HR filings?
Deep Track Capital, LP first reported AXSOME THERAPEUTICS (AXSM) on its 13F-HR filing for the period ending 2023-06-30 (Q2 2023). The position has appeared on 12 reported quarters within Pactolio's tracked window.
What was Deep Track Capital, LP's most recent quarter-over-quarter share-count change in AXSM?
Between Q4 2025 and Q1 2026, Deep Track Capital, LP reduced its AXSM position by 50,000 shares (-4.3%), leaving 1,100,000 shares at a market value of $185.9M.
Does the implied price-per-share represent Deep Track Capital, LP's cost basis in AXSM?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.